Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11771701 | SHORLA | Methotrexate formulation |
Oct, 2034
(10 years from now) | |
US11129833 | SHORLA | Methotrexate formulation |
Oct, 2035
(11 years from now) |
Drugs and Companies using METHOTREXATE ingredient
Market Authorisation Date: 29 November, 2022
Treatment: Treatment of adults with severe psoriasis with an oral solution of methotrexate
Dosage: SOLUTION;ORAL